中华临床免疫和变态反应杂志2026，Vol.20Issue(1)：49-56,8.DOI:10.3969/j.issn.1673-8705.2026.01.006
系统性红斑狼疮的卫生经济学评价研究进展
Progress in health economic evaluations of systemic lupus erythematosus
摘要
Abstract
Systemic lupus erythematosus(SLE)is a chronic autoimmune disease characterized by mul-tisystem involvement and long-term disease burden.In China,both the incidence and prevalence of SLE exceed global averages,with over one million patients affected.As an essential instrument for quantifying disease-relat-ed economic burden,health economic evaluation plays a key role in informing evidence-based decision-making for treatment strategies and healthcare policies.Beginning with an overview of cost-of-illness(COI)analyses in SLE,this review further examines the scope,strengths,limitations,and real-world applications of four major methodologies:cost-effectiveness analysis(CEA),cost-utility analysis(CUA),cost-benefit analysis(CBA),and cost-minimization analysis(CMA).As a result,SLE generates substantial direct,indirect,and intangible costs.While COI studies often emphasize direct medical expenses,productivity loss and deterio-ration in quality of life constitute a significant portion of the overall economic burden and deserve comparable consideration.CEA and CUA are widely employed,particularly for biologics such as belimumab,and frequent-ly demonstrate favorable cost-effectiveness under accepted willingness-to-pay thresholds.In contrast,CBA and CMA remain infrequently used due to methodological challenges.Future research should prioritize the develop-ment of culturally appropriate utility value sets in China and the integrated application of diverse evaluation ap-proaches in local healthcare settings.关键词
系统性红斑狼疮/卫生经济学评价/成本/成本-效果分析/成本-效益分析/成本-效用分析/最小成本法Key words
systemic lupus erythematosus/health economic evaluation/cost/cost-effectiveness anal-ysis/cost-benefit analysis/cost-utility analysis/cost-minimization analysis引用本文复制引用
汪玥,郑可心,李慕聪,吴婵媛,王迁,曾小峰,王艳红,李梦涛..系统性红斑狼疮的卫生经济学评价研究进展[J].中华临床免疫和变态反应杂志,2026,20(1):49-56,8.基金项目
国家重点研发计划项目(2021YFC2501300) （2021YFC2501300）
中央高水平医院临床科研业务费资助(2025-PUMCH-D-001,2022-PUMCH-B-013,2022-PUMCH-C-002,2022-PUMCH-D-009) Chinese National Key Technology R&D Program,Ministry of Science and Technology(2021YFC2501300),National High Level Hospital Clinical Research Funding(2025-PUMCH-D-001,2022-PUMCH-B-013,2022-PUMCH-C-002,2022-PUMCH-D-009) （2025-PUMCH-D-001,2022-PUMCH-B-013,2022-PUMCH-C-002,2022-PUMCH-D-009）
